Financially, CG Oncology reported a net loss of $34.5 million for the three months ended March 31, 2025, compared to $16.9 ...

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, ...

As of March 31, 2025, Aura had cash and cash equivalents and marketable securities totaling $128.0 million. The Company believes its current cash and cash equivalents and marketable securities are ...

Blue Light Cystoscopy with Cysview utilizes a special scope and dye to detect and treat non muscle invasive bladder cancer.

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

The commercial distribution of ANKTIVA commenced in May 2024, and the company believes it has the potential to become a ...

The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...

"The positive results for Imfinzi in the Potomac trial represent a significant advance that will potentially allow more patients with early-stage bladder cancer to benefit from this important ...